Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris

American Journal of Cardiology

Volumn 83, Issue 5, 1999, Pages 643-649

  Van Der Does, Reinhard ^a   Hauf Zachariou, Ulrike ^b   Pfarr, Egon ^b   Holtbrügge, Werner ^a   König, Steffen ^a   Griffiths, Mark ^a   Lahiri, Avijit ^c  

^a IST Studien Therapeutica GmbH   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARVEDILOL; CORONARY VASODILATING AGENT; DIGITALIS; METOPROLOL; MONOAMINE OXIDASE INHIBITOR; NITRATE; PHENOTHIAZINE; PLACEBO; QUINIDINE; RIFAMPICIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; BICYCLE ERGOMETRY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE TEST; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; RESPIRATORY TRACT INFECTION; ST SEGMENT DEPRESSION; SURVIVAL RATE; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; ANGINA PECTORIS; ANTIOXIDANTS; CARBAZOLES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLACEBOS; PROPANOLAMINES; RISK FACTORS; SAFETY; SINGLE-BLIND METHOD; TIME FACTORS; VASODILATOR AGENTS;

EID: 0033105063     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00960-6     Document Type: Article

References (24)

1. Feuerstein G.Z., Poste G., Ruffolo R. Carvedilol update III rationale for use in congestive heart failure . Drugs Today. 31:(suppl F):1995;1-23.
2. Nichols A.J., Sulpizio A.C., Ashton D.J., Hieble J.P., Ruffolo R.R. In vitro pharmacologic profile of the novel β-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology. 39:1989;327-336.
3. Nichols A.J., Sulpizio A.C., Ashton D.J., Hieble J.P., Ruffolo R.R. The interaction of the enantiomers of carvedilol with α1-β1-adrenoceptors. Chirality. 1:1989;265-270.
4. Sponer G., Bartsch W., Strein K., Müller-Beckmann B., Böhm E. Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol. 9:1987;317-327.
5. Ohlstein E.H., Douglas S.A., Sung C.P., Yue T.-L., Louden C., Arleth A., Poste G., Ruffolo R.R., Feuerstein G.Z. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA. 90:1993;6189-6193.
6. Ohlstein E.H., Vickery L., Arleth A., Barone F., Sung C.P., Camden A., McCartney L. Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin Exp Hypertens. 16:1994;163-177.
7. Douglas S.A., Vickery-Clark L.M., Louden C., Ruffolo R.R., Feuerstein G.Z., Ohlstein E.H. Acute pretreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplasty. Pharmacol Commun. 5:1994;65-72.
8. Hamburger S.A., Barone F.C., Feuerstein G.Z., Ruffolo R.R. Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology. 43:1991;113-120.
9. Bril A., Slivjak M., DiMartino M.J., Feuerstein G.Z., Linee P., Poyser R.H., Ruffolo R.R., Smith E.F. Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs comparison with propranolol . Cardiovasc Res. 26:1992;518-525.
10. Feuerstein G.Z., Hamburger S.A., Smith E.F., Bril A., Ruffolo R.R. Myocardial protection with carvedilol. J Cardiovasc Pharmacol. 19:(suppl 1):1992;138-141.
11. Feuerstein GZ, Ruffolo RR. Comparison of the ability of two vasodilating β-blockers, carvedilol and celiprolol, to reduce infarct size in a pig model of acute myocardial infarction. Pharmacol Commun 1994;5:1:57-63.
12. Lopez B.L., Christopher T.A., Yue T.-L., Ruffolo R.R., Feuerstein G.Z., Ma X.-L. Carvedilol, a new β-adrenoceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther. 273:1995;64-71.
13. Yue T.-L., Wang X., Gu J.-L., Ruffolo R.R., Feuerstein G.Z. Carvedilol, a new vasodilating β-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther. 273:1995;1442-1449.
14. Kaski J.C., Rodriguez-Plaza L., Brown J., Maseri A. Efficacy of carvedilol (BM 14.190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. Am J Cardiol. 56:1985;35-40.
15. Rodrigues E.A., Lahiri A., Hughes L.O., Kohli R.S., Whittington J.R., Raftery E.B. Anti-anginal efficacy of carvedilol, a new beta-blocking drug with vasodilating activity. Am J Cardiol. 58:1986;916-921.
16. van der Does R., Eberhardt R., Derr I., Ehmer B., Rudorf J., Überbacher H.J. Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r. Eur Heart J. 12:1991;60-64.
17. Nahrendorf W., Rading A., Steinig G., van der Does R., Schlote A. A comparison of carvedilol with a combination of propranolol/isosorbide-dinitrate in the chronic treatment of stable angina. J Cardiovasc Pharmacol. 19:(suppl 1):1992;114-116.
18. Hauf-Zachariou U., Pfarr E., van der Does R. Carvedilol in comparison and in combination with isosorbide dinitrate sustained release in patients with chronic stable effort-induced angina pectoris. Clin Drug Invest. 14:1997;465-473.
19. DasGupta P., Broadhurst P., Lahiri A., Raftery E.B. Symptomatic and hemodynamic improvement with carvedilol, a vasodilating beta blocker, in patients with congestive heart failure secondary to ischemic heart disease. Am J Cardiol. 66:1990;1118-1123.
20. Olsen S.L., Gilbert E.M., Renlund D.G., Taylor D.O., Yanowitz F.D., Bristow M.R. Carvedilol improves left ventricular function and symptoms in chronic heart failure a double-blind randomized study . J Am Coll Cardiol. 25:1995;1225-1231.
21. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med. 334:1996;1349-1355.
22. Basu S., Senior R., Raval U., van der Does R., Bruckner T., Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction a placebo controlled, randomized trial . Circulation. 95:1997;1-9.
23. Maggi E., Marchesi E., Covini D., Negro C., Perani G., Bellomo G. Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol. 27:1996;532-538.
24. Hauf-Zachariou U., Widmann L., Zülsdorf B., Hennig M., Lang P.D. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol. 45:1993;95-100.